Equities

Tryptamine Therapeutics Ltd

Tryptamine Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.019
  • Today's Change-0.001 / -5.00%
  • Shares traded2.81m
  • 1 Year change+137.50%
  • Beta1.6219
Data delayed at least 20 minutes, as of Jul 04 2024 01:53 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on the development of an advanced and scalable intravenous-infused psilocin formulation, which can be used in conjunction with psychotherapy to address significant unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin). Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.

  • Revenue in AUD (TTM)1.21m
  • Net income in AUD-4.32m
  • Incorporated2013
  • Employees--
  • Location
    Tryptamine Therapeutics LtdC/o Bio101 Financial Advisory Pty LtdSuite 201, 697 Burke Road, CamberwellMELBOURNE 3124AustraliaAUS
  • Phone+61 38419-0827
  • Websitehttps://exopharm.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TYP:ASX since
announced
Transaction
value
TRYP Therapeutics IncAnnounced11 Dec 202311 Dec 2023Announced90.00%4.31m
Data delayed at least 20 minutes, as of Jul 04 2024 01:53 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BTC Health Ltd16.03k-8.26m12.64m1.00--2.337.66788.57-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Tissue Repair Ltd457.52k-3.28m14.81m----0.8601--32.38-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Rhythm Biosciences Ltd157.67k-8.63m14.92m----10.90--94.60-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Medlab Clinical Ltd366.64k-3.94m15.07m14.00------41.11-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Adalta Ltd3.56m-5.04m15.49m----5.65--4.35-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Chimeric Therapeutics Ltd0.00-11.31m16.39m----0.9948-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Patrys Ltd1.70m-5.12m16.46m15.00--3.28--9.71-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Amplia Therapeutics Ltd4.44m-4.50m16.57m1.00--1.07--3.73-0.0226-0.02260.02220.05720.2647--2.05---26.86-25.13-32.90-27.42-----101.48-206.74----0.122--286.42144.8127.86---6.91--
Algorae Pharmaceuticals Ltd84.10k-2.25m16.87m----4.66--200.64-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Noxopharm Ltd3.90m-12.13m19.29m1.00k--2.93--4.94-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
LBT Innovations Limited2.00m-21.38m20.20m17.00--6.42--10.08-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
BPH Energy Ltd345.67k894.65k20.66m2.00k18.370.8882--59.760.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
Alterity Therapeutics Ltd123.46k-12.28m20.98m11.00--0.6361--169.94-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Tryptamine Therapeutics Ltd1.21m-4.32m21.78m----3.24--18.04-0.0162-0.01620.00390.00620.2368-------84.69---120.26-------357.70-----21.620.00--------------
Prescient Therapeutics Ltd697.94k-7.74m31.00m3.00--1.37--44.42-0.0098-0.00980.00090.02810.0276--2.32---30.58-27.61-32.59-29.03-----1,109.58-3,284.78---412.910.00--939.1629.68-36.88------
Invion Ltd4.46m-1.50m32.12m8.00--1.80--7.20-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
Data as of Jul 04 2024. Currency figures normalised to Tryptamine Therapeutics Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.